Stanford review finds painfully few surefire treatments for muscle cramps

February 22, 2010

STANFORD, Calif. -- Most cases of muscle cramps never get reported to public health authorities, so it's difficult to say how common they are. But you probably know someone who's had them. You've probably had them, too. And the older you get, the more likely you're having one right now.

Until not very long ago, quinine -- a bitter-tasting substance sometimes associated with tonic water that was once the world's mainstay treatment for malaria -- was also the drug of choice for treatment of muscle cramps. But in 2006, the Food and Drug Administration warned against the use of quinine for this purpose, not because it was utterly ineffective but because of accumulating anecdotal evidence of adverse effects.

A thorough literature review conducted by researchers at the Stanford University School of Medicine, to be published Feb. 23 in Neurology, confirms the FDA's concerns. The resulting guidelines urge caution in the use of quinine, suggest the exploration of other possible treatments and encourage patients and physicians to pay closer attention to the manifestation of muscle cramps, which are usually benign but can sometimes signal more significant medical problems.

"Our recommendation is that quinine should be avoided for general use in treating muscle cramps," said the study's first author, Hans Katzberg, MD, who has a fellowship in neuromuscular medicine at the medical school. Although available data suggests that quinine can reduce the symptoms by one-third to one-half, serious adverse effects, including blood irregularities, arise as often as one in 25 cases, Katzberg said. Still, if muscle cramps are disabling, other attempted therapies fail and the patient's condition can be actively monitored by a physician, then the use of quinine may be in order. Once sold over the counter, quinine is no longer easily available. It is still a key ingredient in tonic water, but a self-medicating Dr. Schweppes would have to ingest at least a few liters of the stuff a day to get a therapeutic dose. That's a bit of a stretch.

There is no solid formal evidence that either drinking water (tonic or otherwise) or stretching, two frequently cited non-drug approaches to reducing muscle cramps, effectively counters them. Still, neither method is likely to cause much harm if practiced in moderation.

Other muscle-cramp treatments reviewed in this study include vitamin B complex, calcium-channel blocking agents often prescribed for hypertension, and anti-epileptic drugs. But the investigators concluded that more research is needed to assess the efficacy of these alternatives. "The relative lack of data on many of these compounds came as a surprise," said Katzberg.

The review covered only studies of muscle cramps that were unrelated to any underlying disease. Muscle cramps -- typically in the calves, usually more noticeable in the still of the night and frequently experienced by pregnant women -- often occur independently of any underlying serious condition. But they can be indicators of kidney or liver disease as well as neurological conditions, such as Lou Gehrig's disease and peripheral neuropathy associated with late-stage type-2 diabetes. For this reason, people experiencing significant cramping are encouraged to consult a physician.

While breakthrough treatments for muscle cramps remain elusive, the prescription for getting them is no secret: Try sitting and reading 500 journal articles. Katzberg initially sifted through 563 studies on the subject, deeming 24 suitable for analysis. Then he and two colleagues -- senior author Yuen So, MD, PhD, professor of neurology and neurological sciences, and Ahmir Khan, MD, a clinical fellow at the medical school now practicing neurology in Chicago -- carefully read the studies in order to draw their conclusions about different therapies' effectiveness and safety.
-end-
Information about Stanford's Department of Neurology and Neurological Sciences, which supported the work, is available at http://neurology.stanford.edu.

The Stanford University School of Medicine consistently ranks among the nation's top 10 medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://mednews.stanford.edu. The medical school is part of Stanford Medicine, which includes Stanford Hospital & Clinics and Lucile Packard Children's Hospital. For information about all three, please visit http://stanfordmedicine.org/about/news.html.

BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (mamalone@stanford.edu)

Stanford University Medical Center

Related Neurology Articles from Brightsurf:

Lancet Neurology publishes results of AFFiRiS' Phase 1 trial with PD01A in Parkinson's
AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology

Telemedicine effective for monitoring patients in large pediatric neurology network
As the COVID-19 pandemic sent entire communities into lockdown, doctors quickly adopted telehealth strategies without knowing whether they would be effective or feasible.

The Lancet Neurology: Discovery could speed diagnosis and treatment of children with life-threatening neurological diseases
A group of life-threatening neurological conditions affecting children have been linked to an antibody which points to potential treatment, according to an observational multicentre study involving 535 children with central nervous system (CNS) demyelinating disorders and encephalitis, published in The Lancet Neurology journal.

Meaningful change in culture urged to save neurology, reduce gender gap
UC Davis School of Medicine dean, NINDS deputy director lead national charge to improve conditions for women in neurology.

BrainStorm Cell Tx publishes NurOwn ALS Phase 2 randomized trial data in neurology
Results from Brainstorm Cell Therapeutic's NurOwn randomized Phase 2 clinical trial were published in Neurology.

The Lancet Neurology: Pioneering study suggests that an exoskeleton for tetraplegia could be feasible
A whole-body exoskeleton, operated by recording and decoding brain signals, has helped a tetraplegic patient to move all four of his paralysed limbs, according to results of a 2-year trial published in The Lancet Neurology journal.

The Lancet Neurology: Frailty could make people more susceptible to dementia
New research published in The Lancet Neurology journal suggests that frailty makes older adults more susceptible to Alzheimer's dementia, and moderates the effects of dementia-related brain changes on dementia symptoms.

The Lancet Neurology: Cannabis-based drug in combination with other anti-spasticity
Oral spray containing two compounds derived from the cannabis plant reduced spasticity compared with placebo in patients already taking anti-spasticity drugs.

New neurology studies a 'wakeup call' for global health
Neurology experts from around the world will convene Nov. 27 in New Zealand for a Global Brain Summit examining what one calls 'the greatest challenge of societies in the 21st century.' Among the neurological disorders to be discussed at the Summit are stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and migraine and other headaches.

The Lancet Neurology: Daily and weekly cycles of epileptic seizures more common than previously thought
Understanding the pattern of seizures, and how they are linked to circadian rhythms, could be important in improving management of epilepsy.

Read More: Neurology News and Neurology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.